The authors designed SLU-PP-332 from an earlier compound, described as an ERR beta and gamma agonist, by replacing its isopropyl phenyl group with a naphthalene group, aiming at ERR alpha. PubChem's name for the compound, 4-hydroxy-N-[(E)-naphthalen-2-ylmethylideneamino]benzamide, includes that naphthalene group.12
SLU-PP-332 activated all three receptors in a reporter assay in HEK293 cells, with the highest potency at ERR alpha. In C2C12 mouse muscle cells, it raised the activity of the ERR target gene Pdk4 and, after 24 hours, also raised maximum mitochondrial respiration.2









